Metabolomics approach in the investigation of depression biomarkers in pharmacologically induced immune-related depression

PLoS One. 2018 Nov 29;13(11):e0208238. doi: 10.1371/journal.pone.0208238. eCollection 2018.

Abstract

Background: The aim of this study was to identify previously unrecognised biological pathways and biomarkers that might expand the inflammatory hypothesis of depression.

Methods: Broad metabolomics analyses in plasma samples from 31 chronic hepatitis C-infected patients with and without immune-related depression were carried out using the Absolute IDQ p180 kit-a targeted metabolomics approach of combined direct flow injection and liquid chromatography that measures acylcarnitines, amino acids, biogenic amines, glycerophospholipids, sphingolipids, and sugars.

Results: The measurements showed that the average concentration of the branched-chain amino acid isoleucine was significantly lower in depressive HCV patients in comparison to non-depressive HCV patients [depression group: Median 51.35 (43.4-60.2 μmol/L) vs. Median 62.10 (38.4-81.7 μmol/L); U = -2.958; p = 0.002]. All other amino acids, acylcarnitines, biogenic amines, glycerophospholipids, sphingolipids, sugars, liver enzymes and thyroid levels showed no statistically significant differences.

Conclusions: The results of the present study suggest that the branched-chain amino acid isoleucine might play a role in the pathophysiology of immune-related major depression, which expands existing knowledge about inflammatory hypothesis of depression.

MeSH terms

  • Adult
  • Antiviral Agents / adverse effects*
  • Biomarkers / blood
  • Depression / blood*
  • Depression / chemically induced*
  • Depression / complications
  • Female
  • Hepatitis C / blood
  • Hepatitis C / complications
  • Hepatitis C / drug therapy
  • Humans
  • Inflammation / blood
  • Inflammation / chemically induced
  • Inflammation / complications
  • Interferon-alpha / adverse effects*
  • Isoleucine / blood*
  • Male
  • Metabolomics / methods
  • Middle Aged

Substances

  • Antiviral Agents
  • Biomarkers
  • Interferon-alpha
  • Isoleucine

Grants and funding

The authors received no specific funding for this work.